CR20120412A - Compuestos de la supresión de un trastorno del nervio periférico inducido por agente anticancerígeno - Google Patents
Compuestos de la supresión de un trastorno del nervio periférico inducido por agente anticancerígenoInfo
- Publication number
- CR20120412A CR20120412A CR20120412A CR20120412A CR20120412A CR 20120412 A CR20120412 A CR 20120412A CR 20120412 A CR20120412 A CR 20120412A CR 20120412 A CR20120412 A CR 20120412A CR 20120412 A CR20120412 A CR 20120412A
- Authority
- CR
- Costa Rica
- Prior art keywords
- peripheral nerve
- suppression
- compounds
- nerve disorder
- disorder induced
- Prior art date
Links
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 206010060860 Neurological symptom Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010015935 | 2010-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120412A true CR20120412A (es) | 2012-11-13 |
Family
ID=43770309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120412A CR20120412A (es) | 2010-01-27 | 2012-08-07 | Compuestos de la supresión de un trastorno del nervio periférico inducido por agente anticancerígeno |
Country Status (41)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150013143A (ko) * | 2012-04-27 | 2015-02-04 | 니폰 조키 세야쿠 가부시키가이샤 | 트랜스-2-데센산 유도체 및 이것을 함유하는 의약 |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| US9611244B2 (en) | 2015-05-08 | 2017-04-04 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| HRP20260689T1 (hr) | 2015-06-17 | 2026-07-17 | F. Hoffmann-La Roche Ag | Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana |
| RU2742337C2 (ru) * | 2016-09-09 | 2021-02-04 | Такеда Фармасьютикал Компани Лимитед | Циклическое соединение |
| WO2019047812A1 (zh) * | 2017-09-07 | 2019-03-14 | 深圳信立泰药业股份有限公司 | 多西他赛共缀物的药物组合物及制备方法 |
| WO2021012138A1 (zh) | 2019-07-22 | 2021-01-28 | 广州英赛特生物技术有限公司 | 二氨基胍衍生物及其饲用组合物在制备兽医用药物中的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
| EP0252146B1 (en) | 1986-01-09 | 1994-05-25 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| WO1988005083A1 (en) | 1986-12-24 | 1988-07-14 | Whitehead Institute For Biomedical Research | Method of inducible gene expression |
| WO1989007614A1 (en) | 1988-02-12 | 1989-08-24 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| DE68910682T2 (de) | 1988-03-01 | 1994-06-01 | Whitehead Biomedical Inst | Aktivierung der nf-kappa b-vorstufe. |
| AU5419690A (en) | 1989-03-31 | 1990-11-05 | Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5059712A (en) | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
| US5158883A (en) | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
| EP0557290A1 (en) | 1990-08-23 | 1993-09-01 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
| WO1992017168A1 (en) | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
| US6071876A (en) | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
| ES2134804T3 (es) | 1991-04-19 | 1999-10-16 | Childrens Medical Center | Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal. |
| KR19990022369A (ko) * | 1995-06-07 | 1999-03-25 | 스테판 이반스-프레크 | 어뎁터 단백질/티로신 카이나제 상호작용을 방해하는 조성물과그 방법 |
| US20020052019A1 (en) | 1997-11-13 | 2002-05-02 | Genentech Inc | Human toll homologue |
| US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
| WO2001090151A2 (en) | 2000-05-25 | 2001-11-29 | Schering Corporation | Human receptor proteins; related reagents and methods |
| AU1070399A (en) | 1997-10-17 | 1999-05-10 | Genentech Inc. | Human toll homologues |
| ZA989147B (en) | 1997-10-17 | 2000-04-07 | Genentech Inc | Human toll homologues. |
| AU1539499A (en) | 1997-11-25 | 1999-06-15 | Princeton University | Method for preparing adenovirus vectors, vectors so prepared, and uses thereof |
| US20080275104A1 (en) | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US20040072138A1 (en) | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
| DK1063228T5 (da) | 1998-03-09 | 2009-06-15 | Takeda Pharmaceutical | Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf |
| WO2001010826A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | Substituted aromatic-ring compounds, process for producing the same, and use |
| SE9903930D0 (sv) * | 1999-10-29 | 1999-10-29 | Astra Pharma Inc | Novel compounds and a novel process for their preparation |
| CN1416341B (zh) | 2000-02-04 | 2010-05-05 | 武田药品工业株式会社 | 稳定的乳液组合物 |
| CA2685447C (en) | 2000-08-10 | 2013-05-28 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| KR100821546B1 (ko) | 2000-10-18 | 2008-04-11 | 다케다 야쿠힌 고교 가부시키가이샤 | 광학 활성 술폰아미드의 제조 방법 및 그의 합성용 중간체 |
| WO2002045470A1 (fr) | 2000-11-30 | 2002-06-06 | Tokuyama Corporation | Substrat et procede de production correspondant |
| AU2002221099A1 (en) | 2000-12-08 | 2002-06-18 | Takeda Chemical Industries Ltd. | Combination drugs |
| JP5137289B2 (ja) | 2001-08-03 | 2013-02-06 | 武田薬品工業株式会社 | 安定な乳化組成物 |
| EP1495756A4 (en) * | 2002-04-08 | 2009-10-28 | Takeda Pharmaceutical | THERAPEUTIC AGENT FOR SEVERE SEPTIC STATE PREVENTION |
| US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20040259790A1 (en) | 2003-01-30 | 2004-12-23 | Bali Pulendran | Methods for identifying and administering agents that bias the immune response via dendritic cells |
| EP1599726A4 (en) | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
| EP1613956A2 (en) | 2003-03-25 | 2006-01-11 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
| EP1664342A4 (en) | 2003-09-17 | 2007-12-26 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR GENE EXPRESSION |
| WO2005084180A2 (en) | 2003-12-19 | 2005-09-15 | University Of Cincinnati | Polyamides and polyamide complexes for delivery of oligonucleotide decoys |
| MY147790A (en) | 2005-04-28 | 2013-01-31 | Takeda Pharmaceutical | Stable emulsion composition |
| JP5040650B2 (ja) | 2005-06-03 | 2012-10-03 | 小野薬品工業株式会社 | 神経再生および／または保護剤 |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| WO2007091790A1 (en) | 2006-02-07 | 2007-08-16 | Korea Institute Of Radiological & Medical Sciences | A composition for treating damage of central or peripheral nerve system |
| ATE524732T1 (de) | 2006-02-23 | 2011-09-15 | Univ Yale | Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg |
| US7943588B2 (en) | 2006-03-28 | 2011-05-17 | Trustees Of Dartmouth College | Method for preventing or treating neuropathic pain |
| EP1997902B1 (en) | 2006-03-30 | 2013-09-18 | Hiroshima University | Screening method |
| JPWO2007123186A1 (ja) | 2006-04-20 | 2009-09-03 | 武田薬品工業株式会社 | 医薬 |
| JPWO2007132825A1 (ja) | 2006-05-15 | 2009-09-24 | 武田薬品工業株式会社 | 医薬 |
| US20090209585A1 (en) | 2006-07-07 | 2009-08-20 | Takashi Ichikawa | Cycloalkene derivatives, process for production of the derivatives, and use of the same |
| EP1882687A1 (en) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same |
| WO2008112887A1 (en) | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
| WO2009059050A2 (en) | 2007-10-30 | 2009-05-07 | The Regents Of The University Of Colorado | Tlr modulators and methods for using the same |
| EP2262498A2 (en) | 2008-03-10 | 2010-12-22 | Vertex Pharmceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| JP5238381B2 (ja) | 2008-07-07 | 2013-07-17 | スタンレー電気株式会社 | 照明用車両用灯具 |
| EP2480536B1 (en) | 2009-09-23 | 2014-08-13 | The Regents of the University of Colorado, A Body Corporate | Toll-like receptor modulators and uses thereof |
-
2011
- 2011-01-26 SG SG10201503402XA patent/SG10201503402XA/en unknown
- 2011-01-26 MY MYPI2012003414A patent/MY163936A/en unknown
- 2011-01-26 AR ARP110100247A patent/AR080024A1/es unknown
- 2011-01-26 UA UAA201210137A patent/UA109540C2/uk unknown
- 2011-01-26 PL PL11705047T patent/PL2528598T3/pl unknown
- 2011-01-26 PH PH1/2012/501538A patent/PH12012501538A1/en unknown
- 2011-01-26 MA MA35162A patent/MA34014B1/fr unknown
- 2011-01-26 ES ES11705047.6T patent/ES2560215T3/es active Active
- 2011-01-26 HR HRP20160165TT patent/HRP20160165T1/hr unknown
- 2011-01-26 TW TW100102774A patent/TWI481401B/zh not_active IP Right Cessation
- 2011-01-26 CA CA2788150A patent/CA2788150C/en not_active Expired - Fee Related
- 2011-01-26 PT PT117050476T patent/PT2528598E/pt unknown
- 2011-01-26 KR KR1020127021846A patent/KR20120118044A/ko not_active Abandoned
- 2011-01-26 SI SI201130755T patent/SI2528598T1/sl unknown
- 2011-01-26 ME MEP-2016-31A patent/ME02364B/me unknown
- 2011-01-26 PE PE2012001062A patent/PE20121694A1/es not_active Application Discontinuation
- 2011-01-26 NZ NZ601635A patent/NZ601635A/xx not_active IP Right Cessation
- 2011-01-26 WO PCT/JP2011/052077 patent/WO2011093512A1/en not_active Ceased
- 2011-01-26 HU HUE11705047A patent/HUE027310T2/en unknown
- 2011-01-26 DK DK11705047.6T patent/DK2528598T3/en active
- 2011-01-26 AU AU2011211294A patent/AU2011211294B2/en not_active Ceased
- 2011-01-26 MX MX2012008514A patent/MX2012008514A/es not_active Application Discontinuation
- 2011-01-26 BR BR112012018434A patent/BR112012018434A2/pt not_active IP Right Cessation
- 2011-01-26 CN CN201510072433.2A patent/CN104744321A/zh active Pending
- 2011-01-26 JP JP2012533416A patent/JP6131046B2/ja active Active
- 2011-01-26 SG SG2012051967A patent/SG182522A1/en unknown
- 2011-01-26 CN CN201180015681.3A patent/CN102821763B/zh not_active Expired - Fee Related
- 2011-01-26 EP EP11705047.6A patent/EP2528598B1/en active Active
- 2011-01-26 GE GEAP201112845A patent/GEP20166441B/en unknown
- 2011-01-26 EA EA201290697A patent/EA201290697A1/ru unknown
- 2011-01-26 US US13/574,848 patent/US20130046000A1/en not_active Abandoned
- 2011-01-26 RS RS20160076A patent/RS54591B1/sr unknown
- 2011-01-26 UY UY0001033203A patent/UY33203A/es not_active Application Discontinuation
-
2012
- 2012-07-17 TN TNP2012000364A patent/TN2012000364A1/en unknown
- 2012-07-23 IL IL221066A patent/IL221066A/en not_active IP Right Cessation
- 2012-07-25 DO DO2012000209A patent/DOP2012000209A/es unknown
- 2012-07-26 CL CL2012002079A patent/CL2012002079A1/es unknown
- 2012-07-27 ZA ZA2012/05681A patent/ZA201205681B/en unknown
- 2012-08-07 CR CR20120412A patent/CR20120412A/es unknown
- 2012-08-17 CO CO12140288A patent/CO6592110A2/es not_active Application Discontinuation
- 2012-08-27 EC ECSP12012126 patent/ECSP12012126A/es unknown
-
2013
- 2013-08-20 US US13/971,159 patent/US8901171B2/en not_active Expired - Fee Related
-
2014
- 2014-10-28 US US14/525,576 patent/US20150051256A1/en not_active Abandoned
-
2015
- 2015-04-02 US US14/676,947 patent/US20150203464A1/en not_active Abandoned
-
2016
- 2016-02-19 US US15/047,965 patent/US20160166526A1/en not_active Abandoned
- 2016-03-04 CY CY20161100189T patent/CY1117268T1/el unknown
- 2016-03-18 JP JP2016056186A patent/JP2016175903A/ja active Pending
- 2016-04-12 SM SM201600103T patent/SMT201600103B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012126A (es) | Medicamento | |
| BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
| GT201400191A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| MX2015012644A (es) | Tratamiento de cataplejia. | |
| MY173377A (en) | Anti-b7-h3 antibody | |
| MX2019011905A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| MX2019009695A (es) | Inhibidores espirociclicos de catepsina c. | |
| MX2018006503A (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| BR112017003571A2 (pt) | terapia combinada | |
| CL2014000806A1 (es) | Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple. | |
| CO7101239A2 (es) | Composiciones derivadas de la quitosana | |
| GT201500092A (es) | Moduladores de quinolinillo unidos a fenilo de ror-gamma-t | |
| IN2014MN02121A (enExample) | ||
| GT201300263A (es) | Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor | |
| EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
| PH12015502023B1 (en) | Guanidinobenzoic acid ester compound | |
| EP2857037A4 (en) | MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHIC PAIN BY ANTICROBIAL AGENTS | |
| TN2016000213A1 (en) | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder. | |
| MA37475A1 (fr) | Biomarqueurs pour thérapie par inhibiteur de iap | |
| BR112018002763A2 (pt) | método para cicatrização de ferimentos | |
| MX2015016077A (es) | Esteronitronas para el tratamiento y prevencion de ictus o isquemia cerebral, enfermedades de alzheimer, parkinson y esclerosis lateral amiotrofica. | |
| IN2014KN02952A (enExample) | ||
| TR201906539T4 (tr) | Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi. | |
| BR112015001515A2 (pt) | compostos terapêuticos | |
| IN2013MU02469A (enExample) |